Interferon-beta-1a ( DrugBank: Interferon-beta-1a, Interferon-beta )

2 diseases

ID	Disease name (Link within this page)	Number of trials
13	Multiple sclerosis/Neuromyelitis optica	23
97	Ulcerative colitis	1

13. Multiple sclerosis/Neuromyelitis optica

Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

diseases per page:

Showing 1 to 10 of 23 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00441103 (ClinicalTrials.gov)	December 2006	26/2/2007	A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple Scle ...	A Two-arm, Randomized, Double-blind, Control Group-compared, Multicenter, Phase IIIb Study With Mont ...	Multiple Sclerosis, Relapsing-Remitting	Drug: Rebif® New Formulation (IFN-beta-1a, RNF);Drug: Placebo	Merck KGaA	NULL	Completed	18 Years	60 Years	All	180	Phase 3	Canada;Germany;Italy;Russian Federation;Spain;Switzerland
2	EUCTR2006-000606-23-ES (EUCTR)	23/11/2006	15/03/2012	?Post-authorization safety study to check the potential association between the safetyprofile of bet ...	Post-authorization safety study to check the potential association between the safetyprofile of beta ...	Not applicalbe MedDRA version: 14.1;Level: PT;Classification code 10028245;Term: Multiple sclerosis; ...	Trade Name: Rebif 22 y 44 mcg Product Name: Interferon-beta-1a Other descriptive name: INTERFERON BETA ...	Merck, S.L.	NULL	Not Recruiting			Female: yes Male: yes	100	Phase 4	Spain
3	EUCTR2004-001286-17-PT (EUCTR)	08/09/2006	23/03/2006	Exploratory trial to evaluate the risk-benefit ratio of the use of mitoxantrone in patients under tr ...	Exploratory trial to evaluate the risk-benefit ratio of the use of mitoxantrone in patients under tr ...	Relapsing-remitting or relapsing secondary progressive multiple sclerosis with high activity MedDRA ...	Product Name: Mitoxantrone Product Code: N/A	Fundación Española de Esclerosis Múltiple (FEDEM)	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	50		Portugal
4	NCT01134627 (ClinicalTrials.gov)	February 2006	28/5/2010	Minocycline as add-on to Interferon Beta-1a [IFN Beta-1a] (Rebif®) in Relapsing-Remitting Multiple S ...	A Multi-centre, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial Investigating Min ...	Multiple Sclerosis, Relapsing-Remitting	Drug: Minocycline;Drug: Placebo	Merck KGaA	NULL	Terminated	18 Years	55 Years	All	305	Phase 2	Denmark
5	NCT00492765 (ClinicalTrials.gov)	February 2006	25/6/2007	Simvastatin as an Add-on Treatment to Interferon-beta-1afor the Treatment of Relapsing-Remitting Mul ...	A Multi-centre, Double Blind, Randomised, Placebo Controlled, Parallel Group Study Investigating Sim ...	Multiple Sclerosis	Drug: Interferon-beta-1a;Drug: Simvastatin;Drug: Placebo	Biogen Idec	NULL	Completed	18 Years	55 Years	Both	380	Phase 4	Denmark
6	EUCTR2005-004289-18-FI (EUCTR)	26/01/2006	07/11/2005	A Multi-centre, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial Investigating Min ...	A Multi-centre, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial Investigating Min ...	Relapse Remitting Multiple Sclerosis MedDRA version: 8.0;Level: PT;Classification code 10063399	Product Name: Minocycline 100 mg Film-coated Tablets INN or Proposed INN: Minocycline Hydrochloride	Merck AB	NULL	Not Recruiting			Female: yes Male: yes	320		Finland;Sweden
7	EUCTR2005-003930-16-SE (EUCTR)	19/01/2006	21/11/2005	A Multi-centre, Double Blind, Randomised, Placebo Controlled, Parallel Group Study Investigating Sim ...	A Multi-centre, Double Blind, Randomised, Placebo Controlled, Parallel Group Study Investigating Sim ...	Patients with definite relapsing-remitting multiple sclerosis who have never received treatment with ...	Product Name: Simvastatin Alternova INN or Proposed INN: Simvastatin	Biogen Idec A/S	NULL	Not Recruiting			Female: yes Male: yes	380		Finland;Sweden
8	EUCTR2005-003930-16-FI (EUCTR)	05/01/2006	29/11/2005	A Multi-centre, Double Blind, Randomised, Placebo Controlled, Parallel Group Study Investigating Sim ...	A Multi-centre, Double Blind, Randomised, Placebo Controlled, Parallel Group Study Investigating Sim ...	Patients with definite relapsing-remitting multiple sclerosis who have never received treatment with ...	Trade Name: Simvastatin Alternova Product Name: Simvastatin Alternova INN or Proposed INN: Simvastatin ...	Biogen Idec A/S	NULL	Not Recruiting			Female: yes Male: yes	380		Finland;Sweden
9	EUCTR2005-004289-18-SE (EUCTR)	04/01/2006	10/11/2005	A Multi-centre, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial Investigating Min ...	A Multi-centre, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial Investigating Min ...	Relapse Remitting Multiple Sclerosis MedDRA version: 8.0;Level: PT;Classification code 10063399	Product Name: Minocycline 100 mg Film-coated Tablets INN or Proposed INN: Minocycline Hydrochloride	Merck AB	NULL	Not Recruiting			Female: yes Male: yes	320		Finland;Sweden
10	EUCTR2005-004289-18-DK (EUCTR)	19/12/2005	28/11/2005	A Multi-centre, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial Investigating Min ...	A Multi-centre, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial Investigating Min ...	Relapse Remitting Multiple Sclerosis MedDRA version: 8.0;Level: PT;Classification code 10063399	Product Name: Minocycline 100 mg Film-coated Tablets INN or Proposed INN: Minocycline Hydrochloride	E. Merck AB	NULL	Not Recruiting			Female: yes Male: yes	320		Finland;Denmark;Sweden

First Previous1 2 3Next Last

97. Ulcerative colitis

Clinical trials : 2,630 / Drugs : 1,459 - (DrugBank : 265) / Drug target genes : 144 - Drug target pathways : 202

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00303381 (ClinicalTrials.gov)	December 2001	14/3/2006	Safety and Efficacy of Interferon-Beta-1a(Rebif®) for Treating Subjects With Acute Symptoms of Ulcer ...	A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose-finding Phase II Study of Subcutan ...	Ulcerative Colitis	Drug: Interferon-beta-1a, 44 microgram;Drug: Placebo;Drug: Interferon-beta-1a, 66 microgram	EMD Serono	Merck Serono International SA	Completed	18 Years	N/A	Both	194	Phase 2	Germany;Israel;Netherlands;Singapore;Sweden;Switzerland;United Kingdom;Spain

First Previous1Next Last